TuHURA Biosciences, Inc.
HURA
$2.16
-$0.43-16.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.94% | 82.97% | 124.76% | 31.83% | 98.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.12% | 59.75% | 80.41% | 65.14% | 43.25% |
| Operating Income | -14.12% | -59.75% | -80.41% | -65.14% | -43.25% |
| Income Before Tax | -13.09% | -12.77% | -27.31% | -80.88% | -37.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.09% | -12.77% | -27.31% | -80.88% | -37.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.09% | -12.77% | -27.31% | -80.88% | -37.63% |
| EBIT | -14.12% | -59.75% | -80.41% | -65.14% | -43.25% |
| EBITDA | -14.01% | -59.85% | -81.25% | -66.41% | -44.02% |
| EPS Basic | 18.23% | 18.88% | 73.91% | 50.54% | 61.39% |
| Normalized Basic EPS | 12.68% | -14.16% | 70.76% | 70.80% | 63.84% |
| EPS Diluted | 18.23% | 18.88% | 73.91% | 50.54% | 61.39% |
| Normalized Diluted EPS | 12.68% | -14.16% | 70.76% | 70.80% | 63.84% |
| Average Basic Shares Outstanding | 38.26% | 39.03% | 316.03% | 265.85% | 256.55% |
| Average Diluted Shares Outstanding | 38.26% | 39.03% | 316.03% | 265.85% | 256.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.12% | -- | -- | -- | -- |